Published in Autoimmunity on April 19, 2012
Homeostatic regulation of T cell trafficking by a B cell-derived peptide is impaired in autoimmune and chronic inflammatory disease. Nat Med (2015) 2.74
Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol (2015) 1.03
Artesunate abolishes germinal center B cells and inhibits autoimmune arthritis. PLoS One (2014) 0.81
Increased numbers of CD23(+) CD21(hi) Bin-like B cells in human reactive and rheumatoid arthritis lymph nodes. Eur J Immunol (2016) 0.80
MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts. PLoS One (2014) 0.79
Therapeutic effects of PADRE-BAFF autovaccine on rat adjuvant arthritis. Biomed Res Int (2014) 0.78
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther (2016) 0.78
Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Front Immunol (2016) 0.76
Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis. Arthritis Res Ther (2016) 0.75
B cell receptor signaling-based index as a biomarker for the loss of peripheral immune tolerance in autoreactive B cells in rheumatoid arthritis. PLoS One (2014) 0.75
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Predominant autoantibody production by early human B cell precursors. Science (2003) 13.14
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94
Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature (1988) 9.17
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
B cells regulate autoimmunity by provision of IL-10. Nat Immunol (2002) 7.30
A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity (2008) 6.73
Organ-specific disease provoked by systemic autoimmunity. Cell (1996) 6.44
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med (1957) 5.79
An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science (2001) 5.73
Receptor editing in self-reactive bone marrow B cells. J Exp Med (1993) 5.49
Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (1989) 5.48
Arthritis critically dependent on innate immune system players. Immunity (2002) 5.31
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 5.13
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science (2001) 4.79
Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol (2000) 4.73
Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity (2002) 4.60
Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol (2006) 4.46
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity (2004) 4.42
Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature (1994) 4.36
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28
Prevention of arthritis by interleukin 10-producing B cells. J Exp Med (2003) 4.27
Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med (2005) 4.16
Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol (2001) 4.03
Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity (2004) 4.00
Serum transfer of collagen-induced arthritis in mice. J Exp Med (1983) 3.74
Lymphoid neogenesis in rheumatoid synovitis. J Immunol (2001) 3.63
B70 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 3.57
Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 3.56
CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol (1991) 3.47
Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol (2007) 3.09
The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol (2009) 2.87
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A (2007) 2.81
BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity (2000) 2.79
T cell activation in rheumatoid synovium is B cell dependent. J Immunol (2001) 2.73
Treatment of murine lupus with CTLA4Ig. Science (1994) 2.69
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 2.45
Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med (2005) 2.39
Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A (1996) 2.36
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum (2005) 2.30
B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol (1995) 2.29
Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med (2009) 2.19
Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum (2006) 2.17
Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med (1994) 2.15
CD40 signaling activates CD11a/CD18 (LFA-1)-mediated adhesion in B cells. J Immunol (1991) 2.04
Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol (2005) 1.96
Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis (2011) 1.96
Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol (2004) 1.89
Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med (2003) 1.85
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol (2000) 1.77
BLyS and APRIL in rheumatoid arthritis. J Clin Invest (2005) 1.75
Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J Immunol (2005) 1.74
Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol (1999) 1.71
Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J Immunol (2008) 1.69
Production of cytokines by human B cells in health and disease. Immunol Today (1997) 1.66
Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis (2007) 1.65
Antigen presentation by hapten-specific B lymphocytes. II. Specificity and properties of antigen-presenting B lymphocytes, and function of immunoglobulin receptors. J Immunol (1985) 1.64
BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci (2005) 1.64
Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum (2011) 1.62
Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol (2008) 1.62
Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. J Immunol (1994) 1.61
The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev (2009) 1.58
Persistent expression of autoantibodies in SLE patients in remission. J Exp Med (2006) 1.56
Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis. Arthritis Rheum (2007) 1.52
The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum (2011) 1.51
Complement deficiency ameliorates collagen-induced arthritis in mice. J Immunol (2002) 1.51
Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis (2008) 1.47
Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis (2008) 1.40
Textbook germinal centers? J Immunol (2004) 1.38
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2006) 1.34
Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur J Immunol (1996) 1.31
Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol (2007) 1.28
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther (2009) 1.27
A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci U S A (2009) 1.26
CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol (1995) 1.25
Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol (1996) 1.24
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum (2007) 1.23
Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J Immunol (2002) 1.16
Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol (2002) 1.14
T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol (1994) 1.08
Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. Arthritis Res Ther (2009) 1.06
The B lymphocyte in rheumatoid arthritis: analysis of rearranged V kappa genes from B cells infiltrating the synovial membrane. Eur J Immunol (1995) 1.05
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther (2008) 1.05
Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) (2006) 1.05
B cells from rheumatoid arthritis patients show important alterations in the expression of CD86 and FcgammaRIIb, which are modulated by anti-tumor necrosis factor therapy. Arthritis Res Ther (2010) 1.04
IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol (1994) 1.04
Differential requirements for expression of CD80/86 and CD40 on B cells for T-dependent antibody responses in vivo. J Immunol (2003) 1.02
Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis. Arthritis Res (2000) 1.01
Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis. Am J Pathol (2001) 1.00
Resource competition as a mechanism for B cell homeostasis. Proc Natl Acad Sci U S A (1997) 0.99
Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis (2008) 0.99
IL-4 and IL-2 upregulate the expression of antigen B7, the B cell counterstructure to T cell CD28: an amplification mechanism for T-B cell interactions. Int Immunol (1991) 0.97
Specific B lymphocytes efficiently pick up, process and present antigen to T cells. Behring Inst Mitt (1985) 0.96
Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. J Pathol (2004) 0.95
B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J Immunol (2011) 1.59
Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol (2011) 1.59
Development of proteoglycan-induced arthritis is independent of IL-17. J Immunol (2008) 1.36
Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol (2007) 1.28
IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J Immunol (2009) 1.18
CCR5 is involved in resolution of inflammation in proteoglycan-induced arthritis. Arthritis Rheum (2009) 0.87
B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis. Eur J Immunol (2015) 0.78